XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
Go back to XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer| (NASDAQ: XBIT) | Delayed: 1.93 -0.04 (2.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.97 | 52 Week High | $25.00 | |||
| Open | $1.95 | 52 Week Low | $6.36 | |||
| Day High | $1.95 | P/E | N/A | |||
| Day Low | $1.86 | EPS | $0.00 | |||
| Volume | 121,737 | |||||



